- Report
- May 2025
- 191 Pages
Global
From €4488EUR$4,950USD£3,836GBP
- Report
- May 2025
- 102 Pages
Global
From €2675EUR$2,950USD£2,286GBP
- Report
- May 2025
- 80 Pages
Middle East, Africa
From €2675EUR$2,950USD£2,286GBP
- Report
- May 2025
- 80 Pages
From €2675EUR$2,950USD£2,286GBP
- Report
- May 2025
- 95 Pages
Asia Pacific
From €3128EUR$3,450USD£2,674GBP
- Report
- May 2025
- 96 Pages
Europe
From €3128EUR$3,450USD£2,674GBP
- Report
- May 2025
- 87 Pages
North America
From €2675EUR$2,950USD£2,286GBP
- Report
- April 2025
- 145 Pages
Global
From €4397EUR$4,850USD£3,758GBP
- Report
- October 2024
- 202 Pages
Global
From €2221EUR$2,450USD£1,899GBP
- Report
- September 2024
- 115 Pages
Global
From €4080EUR$4,500USD£3,487GBP
- Report
- March 2024
- 118 Pages
Global
From €4080EUR$4,500USD£3,487GBP
- Report
- March 2024
- 221 Pages
Global
From €2221EUR$2,450USD£1,899GBP
- Report
- February 2024
- 116 Pages
Global
From €4524EUR$4,990USD£3,867GBP
- Report
- October 2023
- 85 Pages
United States
From €4397EUR$4,850USD£3,758GBP
- Report
- August 2023
- 66 Pages
Global
€7254EUR$8,000USD£6,200GBP
- Report
- August 2023
- 63 Pages
Vietnam
From €1809EUR$1,995USD£1,546GBP
- Report
- June 2023
- 65 Pages
Global
From €4488EUR$4,950USD£3,836GBP
- Training
- May 2023
- 2 Days
Global
From €1420EUR$1,566USD£1,214GBP
€1671EUR$1,843USD£1,428GBP
- Report
- January 2023
- 28 Pages
Global
From €1224EUR$1,350USD£1,046GBP
- Report
- November 2022
- 220 Pages
Global
From €3128EUR$3,450USD£2,674GBP

The Biosimilar market is a subset of the biotechnology industry that focuses on the development and production of biologic drugs that are similar to existing biologic drugs. Biosimilars are created using a process called recombinant DNA technology, which involves the manipulation of genetic material to create a drug that is similar to an existing biologic drug. Biosimilars are typically used to treat chronic conditions such as cancer, rheumatoid arthritis, and multiple sclerosis. Biosimilars are typically cheaper than their brand-name counterparts, making them an attractive option for patients and healthcare providers.
Some companies in the Biosimilar market include Amgen, Biocon, Celltrion, Dr. Reddy's Laboratories, Mylan, Pfizer, Sandoz, and Teva Pharmaceuticals. Show Less Read more